In the sole prospective phase III trial published so far, the Checkmate 143 trial, PD-L1 tumor expression was determined retrospectively by a central laboratory on archival tumor tissue from first surgery or recurrence, with PD-L1 positivity defined as membranous staining in ≥1% of tumor cells. The gene discussed is CD274; the disease is neoplasm.